plague vaccine

Vaccineapproved

Approved

May 14, 1942

Plague vaccine is a vaccine used against Yersinia pestis to prevent the plague. Inactivated bacterial vaccines have been used since 1890 but are less effective against the pneumonic plague, so live, attenuated vaccines and recombinant protein vaccines have been developed to prevent the disease. — Wikipedia

Clinical trial activity

2 trials · 2 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 2014 (NCT02596308)

Timeline

1940s

  1. May 14, 1942

    Earliest FDA Approval

1990s

  1. Oct 5, 1994

    Greer Laboratories — First NDA Organization

  2. Oct 5, 1994

    Greer Laboratories — NDA Secondary Org

  3. Oct 5, 1994

    Greer Laboratories — NDA Organization

2010s

  1. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetOTHER

    Biological vaccine - induces immune response

  • Yersinia pestisImmunity, active

    Yersinia pestis immunity, active

Approval history

  • approvedMay 14, 1942

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • plague vaccine
  • plague vaccine
  • plague vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05330624Phase 2May 8, 2020Government of China
NCT02596308Phase 2Oct 1, 2014China National Biotec Group Co., Ltd, Government of China
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of ChinaGovernment2212014
China National Biotec Group Co., LtdFor profit1012014
2 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
Greer LaboratoriesFor profitNDA2Oct 5, 1994
Greer LaboratoriesFor profitNDAOct 5, 1994